Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and ...
For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback